Evidence map›Paper›PMID 38862960›Full record

ArticleNutrition journal2024

Relationship between sex, APOE genotype, endocannabinoids and cognitive change in older adults with metabolic syndrome during a 3-year Mediterranean diet intervention.

Natalia Soldevila-Domenech, Beatriz Fagundo, Aida Cuenca-Royo, Laura Forcano, Maria Gomis-González, Anna Boronat, Antoni Pastor, Olga Castañer, Maria Dolores Zomeño, Albert Goday and 9 more

Abstract read
In one paragraph

Article in Nutrition journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Natalia Soldevila-DomenechIntegrative Pharmacology and Systems Neurosciences Research Group, Neurosciences Research Program, Hospital del Mar Research Institute (HMRI), Barcelona, 08003, Spain.ORCID http://orcid.org/0000-0001-6024-8508
Beatriz FagundoIntegrative Pharmacology and Systems Neurosciences Research Group, Neurosciences Research Program, Hospital del Mar Research Institute (HMRI), Barcelona, 08003, Spain.ORCID http://orcid.org/0000-0003-1703-9457
Aida Cuenca-RoyoIntegrative Pharmacology and Systems Neurosciences Research Group, Neurosciences Research Program, Hospital del Mar Research Institute (HMRI), Barcelona, 08003, Spain.ORCID http://orcid.org/0000-0001-8551-5457
Laura ForcanoIntegrative Pharmacology and Systems Neurosciences Research Group, Neurosciences Research Program, Hospital del Mar Research Institute (HMRI), Barcelona, 08003, Spain.ORCID http://orcid.org/0000-0002-8478-1451
Maria Gomis-GonzálezIntegrative Pharmacology and Systems Neurosciences Research Group, Neurosciences Research Program, Hospital del Mar Research Institute (HMRI), Barcelona, 08003, Spain.ORCID http://orcid.org/0000-0001-9778-4849
Anna BoronatIntegrative Pharmacology and Systems Neurosciences Research Group, Neurosciences Research Program, Hospital del Mar Research Institute (HMRI), Barcelona, 08003, Spain.ORCID http://orcid.org/0000-0003-0852-3634
Antoni PastorIntegrative Pharmacology and Systems Neurosciences Research Group, Neurosciences Research Program, Hospital del Mar Research Institute (HMRI), Barcelona, 08003, Spain.ORCID http://orcid.org/0000-0003-3692-0696
Olga CastañerCIBER de Fisiopatología de la Obesidad y Nutrición, Instituto de Salud Carlos III, Madrid, 28029, Spain.ORCID http://orcid.org/0000-0003-3169-997X
Maria Dolores ZomeñoCIBER de Fisiopatología de la Obesidad y Nutrición, Instituto de Salud Carlos III, Madrid, 28029, Spain.ORCID http://orcid.org/0000-0003-1280-7680
Albert GodayCIBER de Fisiopatología de la Obesidad y Nutrición, Instituto de Salud Carlos III, Madrid, 28029, Spain.ORCID http://orcid.org/0000-0001-7356-1595
Mara DierssenDepartment of Medicine and Life Sciences, Universitat Pompeu Fabra, Barcelona, 08003, Spain.ORCID http://orcid.org/0000-0003-0853-6865
Khashayar Baghizadeh HosseiniDepartment of Medicine and Life Sciences, Universitat Pompeu Fabra, Barcelona, 08003, Spain.ORCID http://orcid.org/0000-0002-4644-6986
Emilio RosCIBER de Fisiopatología de la Obesidad y Nutrición, Instituto de Salud Carlos III, Madrid, 28029, Spain.ORCID http://orcid.org/0000-0002-2573-1294
Dolores CorellaCIBER de Fisiopatología de la Obesidad y Nutrición, Instituto de Salud Carlos III, Madrid, 28029, Spain.ORCID http://orcid.org/0000-0002-2366-4104
Miguel Ángel Martínez-GonzálezCIBER de Fisiopatología de la Obesidad y Nutrición, Instituto de Salud Carlos III, Madrid, 28029, Spain.ORCID http://orcid.org/0000-0002-3917-9808
Jordi Salas-SalvadóCIBER de Fisiopatología de la Obesidad y Nutrición, Instituto de Salud Carlos III, Madrid, 28029, Spain.ORCID http://orcid.org/0000-0003-2700-7459
Fernando Fernández-ArandaCIBER de Fisiopatología de la Obesidad y Nutrición, Instituto de Salud Carlos III, Madrid, 28029, Spain.ORCID http://orcid.org/0000-0002-2968-9898
Montserrat FitóCIBER de Fisiopatología de la Obesidad y Nutrición, Instituto de Salud Carlos III, Madrid, 28029, Spain.ORCID http://orcid.org/0000-0002-1817-483X
Rafael de la TorreDepartment of Medicine and Life Sciences, Universitat Pompeu Fabra, Barcelona, 08003, Spain. rtorre2@researchmar.net.ORCID http://orcid.org/0000-0002-6765-1866

Funding

Agència de Gestió d'Ajuts Universitaris i de Recerca FI_B2021/00104Departament de Salut, Generalitat de Catalunya SLT006/17/00246, SLT002/16/00045 and SLT006/17/00077Generalitat de Catalunya 2017 SGR 138Generalitat Valenciana PROMETEO/2017/017; Grant FEA/SEA 2017 for Primary Care ResearchH2020 European Institute of Innovation and Technology Eat2beNICE/ H2020-SFS-2016-2; Ref 728018; and PRIME/ H2020-SC1-BHC-2018-2020; Ref: 847879HORIZON EUROPE European Research Council Advanced Research Grant 2014-2019; agreement #340918Instituto de Salud Carlos III PI13/00233, PI13/00728, PI13/01123, PI13/00462, PI16/00533, PI16/00366, PI16/01094, PI16/00501, PI17/01167, PI19/00017, PI19/00781, PI19/01032, PI19/00576'la Caixa' Foundation 2013ACUP00194
6 · The paper itself

Abstract

backgroundThe Mediterranean diet (MedDiet) has demonstrated efficacy in preventing age-related cognitive decline and modulating plasma concentrations of endocannabinoids (eCBs) and N-acylethanolamines (NAEs, or eCB-like compounds), which are lipid mediators involved in multiple neurological disorders and metabolic processes. Hypothesizing that eCBs and NAEs will be biomarkers of a MedDiet intervention and will be related to the cognitive response, we investigated this relationship according to sex and apolipoprotein E (APOE) genotype, which may affect eCBs and cognitive performance.

methodsThis was a prospective cohort study of 102 participants (53.9% women, 18.8% APOE-ɛ4 carriers, aged 65.6 ± 4.5 years) from the PREDIMED-Plus-Cognition substudy, who were recruited at the Hospital del Mar Research Institute (Barcelona). All of them presented metabolic syndrome plus overweight/obesity (inclusion criteria of the PREDIMED-Plus) and normal cognitive performance at baseline (inclusion criteria of this substudy). A comprehensive battery of neuropsychological tests was administered at baseline and after 1 and 3 years. Plasma concentrations of eCBs and NAEs, including 2-arachidonoylglycerol (2-AG), anandamide (AEA), oleoylethanolamide (OEA), palmitoylethanolamide (PEA), and N-docosahexaenoylethanolamine (DHEA), were also monitored. Baseline cognition, cognitive changes, and the association between eCBs/NAEs and cognition were evaluated according to gender (crude models), sex (adjusted models), and APOE genotype.

resultsAt baseline, men had better executive function and global cognition than women (the effect size of gender differences was - 0.49, p = 0.015; and - 0.42, p = 0.036); however, these differences became nonsignificant in models of sex differences. After 3 years of MedDiet intervention, participants exhibited modest improvements in memory and global cognition. However, greater memory changes were observed in men than in women (Cohen's d of 0.40 vs. 0.25; p = 0.017). In men and APOE-ε4 carriers, 2-AG concentrations were inversely associated with baseline cognition and cognitive changes, while in women, cognitive changes were positively linked to changes in DHEA and the DHEA/AEA ratio. In men, changes in the OEA/AEA and OEA/PEA ratios were positively associated with cognitive changes.

conclusionsThe MedDiet improved participants' cognitive performance but the effect size was small and negatively influenced by female sex. Changes in 2-AG, DHEA, the OEA/AEA, the OEA/PEA and the DHEA/AEA ratios were associated with cognitive changes in a sex- and APOE-dependent fashion. These results support the modulation of the endocannabinoid system as a potential therapeutic approach to prevent cognitive decline in at-risk populations.

trial registrationISRCTN89898870.

Indexed as

CognitionDiet, MediterraneanEndocannabinoidsGenotypeMetabolic SyndromeAgedAmidesApolipoproteins EArachidonic AcidsBiomarkersEthanolaminesFemaleGlyceridesHumansMaleMiddle AgedAmidesanandamideApoE protein, humanApolipoproteins EArachidonic AcidsBiomarkersEndocannabinoidsEthanolaminesGlyceridesglyceryl 2-arachidonateN-acylethanolaminesOleic AcidsoleoylethanolamidepalmidrolPalmitic AcidsPolyunsaturated Alkamides2-AGCognitionEndocannabinoidsMediterranean dietMetabolic syndromeSex differences

Identifiers

PMID38862960
PMCPMC11167771

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.